| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1263 | Cbs-3595 | Novel Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα -related Diseases |
|
| DCC1264 | Cbtf-ee | The first Gatekeeper RXR antagonist that does not show allosteric inhibition in permissive RXR heterodimers, binding domain (LBD) at the entrance of the ligand binding pocket (LBP), blocking access to the LBP and thus serving as a gatekeeper |
|
| DCC1265 | Cbz-FTY720 | FTY720 derivative |
|
| DCC1266 | Cc0651 | Novel inhibitor of the E2 ubiquitin-conjugating enzyme Cdc34A |
|
| DCC1267 | Cc-3060 | Novel Cereblon modulator, promoting ZBTB16 degradation by primarily engaging distinct structural degrons on CRBN-ZnF1 zinc finger domains |
|
| DCC1268 | Cc34301 | PqsE inhibitor, binding to the active center inhibiting PqsE's thioesterase activity in cell-based and in vitro assays |
|
| DCC1269 | Cc41801 | PqsE inhibitor, binding to the active center inhibiting PqsE's thioesterase activity in cell-based and in vitro assays |
|
| DCC1270 | Cc-509 | Novel potent orally bioavailable Syk kinase inhibitor |
|
| DCC1271 | Cc-647 | Novel Cereblon modulator, promoting ZBTB16 degradation by primarily engaging distinct structural degrons on CRBN-ZnF3 zinc finger domains |
|
| DCC1272 | Ccdc919159 | Novel Indigoid Anti-tuberculosis Agent; Antimicrobial |
|
| DCC1273 | C-ceritinib Tfa Salt | Novel coupleable ceritinib analog with a linker, also binding multiple other kinases, including FAK1, RSK1/2, ERK1/2, CAMKK2 and FER |
|
| DCC1274 | Ccg-120304 | Novel Inhibitor of TonB Function |
|
| DCC1275 | Ccg-175472 | Novel Inhibitor of TonB Function |
|
| DCC1276 | ccg-206559 | Potent photoprobe as Rho/MKL1/SRF transcription inhibitor |
|
| DCC1277 | Ccg-206584 | Novel inhibitor of G Protein-Coupled Receptor Kinase |
|
| DCC1278 | Ccg-265328 | Novel covalent selective GRK inhibitor, interacting with a nonconserved cysteine (Cys474) |
|
| DCC1279 | Ccg-46842 | Novel sialyltransferase inhibitor (IC 50 : 2 µM) |
|
| DCC1280 | Cci7967 | Novel MmpL3 inhibitor |
|
| DCC1281 | (E/Z)-CCR-11 Featured | (E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ. |
.gif)
|
| DCC1282 | Ccr4-in-22 | Novel CCR4 antagonist, enhancing DC activation and homing to the regional lymph node and showing potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment |
|
| DCC1283 | Cct245718 | Novel dual FLT3/Aurora A inhibitor, overcoming D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells |
|
| DCC1284 | Cct245731 | Inactive analogue of pictilisib to be used as the negative control |
|
| DCC1285 | Cct245737(s) | Highly Selective Oral Checkpoint Kinase 1 (CHK1) Inhibitor |
|
| DCC1286 | Cct365386 | Novel inhibitor of BCL6 |
|
| DCC1287 | Ccta-1523 | Novel inhibitor of the efflux function of ABCG2, selectively reversing ABCG2-mediated MDR in cancer cells in vitro and in vivo |
|
| DCC1288 | Ccw 28-3 | Novel potent covalent BRD4 degrader, degrading BRD4 in a proteasome- and RNF4-dependent manner without inhibiting RNF4 autoubiquitination activity |
|
| DCC1289 | Cd08108 | Novel MC1R agonist |
|
| DCC1290 | Cd10847 | Novel Caspase-1 inhibitor |
|
| DCC1291 | cd11359 | Novel telomerase inhibitor |
|
| DCC1292 | Cd2019 | Retinoic acid receptor beta (RARbeta) agonist, overcoming inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord. |
|
